Icaritin/ZKAB 001

Drug Profile

Icaritin/ZKAB 001

Alternative Names: IC-162/ZKAB-001; Icaritin/STI-A1014; Icaritin/ZKAB001; PD-L1 monoclonal antibody - Lees Pharmaceutical Holdings; SNG-162/STI-A1014; SNG-162/ZKAB-001; STI-A1014/Icaritin; STI-A1014/SNG-162; ZKAB-001/IC-162; ZKAB-001/Icaritin

Latest Information Update: 27 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lees Pharmaceutical Holdings; Shenogen Pharma
  • Class Antineoplastics; Benzopyrans; Flavonoids; Monoclonal antibodies; Phenyl ethers; Small molecules
  • Mechanism of Action Estrogen receptor alpha modulators; PDCD 1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 20 Nov 2017 Early research in Cancer in China (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top